Raymond James Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
FBR Capital Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
February 29, 2016 6:48 AM ESTFBR Capital upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform with a price target of $10.00.
Analyst Christopher James commented, "We are upgrading KERX shares to Outperform from Market Perform, based on our valuation of the shares relative to current price levels, and maintaining our current price target of $10. On February 25, Keryx... More
JPMorgan Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
February 26, 2016 7:09 AM ESTJPMorgan downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Overweight to Neutral and removed its price target (prior $11.00).
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $3.34 yesterday.
... MoreKeryx Biopharma (KERX) Misses Q4 EPS by 11c
February 25, 2016 7:14 AM ESTKeryx Biopharma (NASDAQ: KERX) reported Q4 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.68 million.
As we enter 2016, the fundamentals of Auryxia are solid, and we plan to... More
